British Columbia Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

British Columbia Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-359,000	Closed	-$34.1M	–	791
2024 Q1	$34.1M	Hold	359,000	–	–	0.24%	90
2023 Q4	$32.1M	Buy	359,000 +44,000	+14%	+$3.27M	0.26%	79
2023 Q3	$23M	Hold	315,000	–	–	0.22%	94
2023 Q2	$26.2M	Buy	315,000 +20,000	+7%	+$1.67M	0.24%	86
2023 Q1	$22.5M	Buy	295,000 +115,000	+64%	+$9.54M	0.23%	78
2022 Q4	$14.9M	Buy	180,000 +97,500	+118%	+$7.89M	0.16%	110
2022 Q3	$6.54M	Buy	+82,500	New	+$6.96M	0.07%	228

Other funds holding XBI

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

British Columbia Investment Management's XBI Position: Q2 2024 in Review

British Columbia Investment Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 359,000 shares — an estimated $34.1M sold.

British Columbia Investment Management first reported a position in XBI in Q3 2022 and held it in 7 quarters. The position peaked at $34.1M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

British Columbia Investment Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
British Columbia Investment Management sold 359,000 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $34.1M.
British Columbia Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 7 quarters.
British Columbia Investment Management's State Street SPDR S&P Biotech ETF position peaked at $34.1M in Q1 2024.
761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on British Columbia Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.